Drugs & Targets FDA approves BMS cell-manufacturing facility in Massachusetts June 09, 2023Vol.49 No.23
Drugs & Targets FDA approves Lynparza with abiraterone, prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer June 02, 2023Vol.49 No.22
Drugs & Targets FDA approves Posluma—first radiohybrid PSMA-targeted PET imaging agent for prostate cancer June 02, 2023Vol.49 No.22
Drugs & Targets FDA grants priority review to repotrectinib for locally advanced or metastatic ROS1-positive NSCLC June 02, 2023Vol.49 No.22
Drugs & Targets EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence June 02, 2023Vol.49 No.22
Drugs & Targets Lifebit, Flatiron Health partner to accelerate cancer data research June 02, 2023Vol.49 No.22
Drugs & Targets Leal Health establishes proprietary platform for oncologists to obtain personalized clinical trial matches for patients June 02, 2023Vol.49 No.22
Drugs & Targets FDA grants accelerated approval to Epkinly for R/R DLBCL and high-grade B-cell lymphoma May 26, 2023Vol.49 No.21
Drugs & Targets Wistar Institute, Pennsylvania Biotechnology Center, Baruch S. Blumberg Institute collaborate to support regional biotech startups May 19, 2023Vol.49 No.20
Drugs & Targets Atlantic Health System forms partnership with NCI’s Cooperative Human Tissue Network May 19, 2023Vol.49 No.20
